Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
Compositions and methods that rapidly and selectively modify hematopoietic stem cells (or cells derived therefrom) to achieve therapeutic objectives by providing for transient expression of nucleic acids are described. The transient expression leads to permanent therapeutic changes in the modified cells, referred to herein as “hit and run” effects.
1. A method of selectively modifying a selected cell population of hematopoietic origin comprising:
(a) forming selected cell-targeted synthetic nanocarriers by
(i) adding polyglutamic acid (PGA) conjugated to selected cell targeting ligands that bind the selected cell population of hematopoietic origin to a solution comprising nucleic acid encapsulated within a positively-charged carrier comprising poly(β-amino ester); and
(ii) incubating the solution wherein selected cell-targeted synthetic nanocarriers form within 5 minutes of the adding and comprise
(A) nucleic acid encapsulated within the positively-charged carrier comprising poly(β-amino ester);
(B) a neutrally or negatively-charged coating comprising about a 15 kDa PGA on the outer surface of the positively-charged carrier; and
(C) the selected cell targeting ligands extending from the outer surface of the neutrally or negatively-charged coating and conjugated to PGA within the neutrally or negatively-charged coating; and
(b) administering the formed selected cell-targeted synthetic nanocarriers to a heterogenous mixture of ex vivo cells comprising the selected cell population of hematopoietic origin within a serum-free media thereby selectively modifying the selected cell population of hematopoietic origin.
2. A method of claim 1 wherein the nucleic acid encodes a megaTAL of SEQ ID NO: 1 or a humanized chimeric antigen receptor of SEQ ID NO: 37.
3. A method of claim 1 wherein the nucleic acid is synthetic mRNA.
4. A method of claim 3 wherein the synthetic mRNA encodes a gene editing agent selected from transcription activator-like effector nucleases (TALENs); megaTALs; and/or zinc finger nucleases.
5. A method of claim 3 wherein the synthetic mRNA encodes a phenotype-altering protein selected from FOXO1, LKB1, TCF7, EOMES, ID2, TERT, CCR2b, and/or CCR4.
6. A method of claim 1 wherein the selected cell population of hematopoietic origin is selected from T cells, natural killer cells, monocytes, macrophages, dendritic cells, B cells, or hematopoietic stem cells.
7. A method of claim 1 wherein the selected cell targeting ligand comprises a CD4 binding domain or a CD8 binding domain.
8. A method of claim 1 wherein no cell selection or purification processes that increase the percentage of the selected cell population relative to other cells within the heterogenous mixture are performed prior to the administering.